Development of drugs for antimicrobial-resistant pathogens

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antimicrobial resistance (AMR) has been linked to antimicrobial use for over 50 years.
• Multidrug-resistant organisms pose significant treatment challenges due to limited therapeutic options.
• Pharmaceutical companies are reducing investment in the development of new antimicrobial agents.

Purpose of the Study:

• To review initiatives aimed at addressing antimicrobial resistance.
• To highlight strategies for developing new antimicrobial drugs and promoting appropriate use of existing ones.

Main Methods:

• Review of US Food and Drug Administration (FDA) initiatives for identifying priority pathogens.
• Examination of streamlined drug development processes for antimicrobial agents.
• Analysis of federal agency programs for clinician and public education on antimicrobial stewardship.

Main Results:

• The FDA is identifying critical pathogens and facilitating antimicrobial drug development.
• Federal agencies are implementing educational programs to promote appropriate antimicrobial use.
• There is a recognized need to balance the development of novel antimicrobial agents with the preservation of current therapies.

Conclusions:

• Addressing antimicrobial resistance requires a dual approach: fostering new drug innovation and ensuring prudent use of existing antimicrobial agents.
• Striking a balance between promoting new antimicrobial development and preserving the efficacy of current drugs is essential for public health.
• Effective antimicrobial stewardship programs are vital to combat the growing threat of multidrug-resistant organisms.